Ironwood Pharmaceuticals (IRWD) Common Equity (2016 - 2025)
Ironwood Pharmaceuticals (IRWD) has disclosed Common Equity for 17 consecutive years, with -$261.8 million as the latest value for Q4 2025.
- Quarterly Common Equity rose 13.11% to -$261.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$261.8 million through Dec 2025, up 13.11% year-over-year, with the annual reading at -$261.8 million for FY2025, 13.11% up from the prior year.
- Common Equity hit -$261.8 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$264.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $706.9 million in Q1 2023 to a low of -$346.8 million in Q2 2023.
- Historically, Common Equity has averaged $85.0 million across 5 years, with a median of -$132.4 million in 2023.
- Biggest five-year swings in Common Equity: surged 9722.85% in 2021 and later tumbled 9841.77% in 2024.
- Year by year, Common Equity stood at $605.9 million in 2021, then rose by 7.67% to $652.4 million in 2022, then tumbled by 100.46% to -$3.0 million in 2023, then crashed by 9841.77% to -$301.3 million in 2024, then increased by 13.11% to -$261.8 million in 2025.
- Business Quant data shows Common Equity for IRWD at -$261.8 million in Q4 2025, -$264.2 million in Q3 2025, and -$308.2 million in Q2 2025.